New hope for myeloma: Head-to-Head trial of two advanced therapies

NCT ID NCT07518186

First seen Apr 09, 2026 · Last updated Jun 10, 2026 · Updated 9 times

Summary

This study tests a new drug, JNJ-79635322, against another drug called teclistamab in people with multiple myeloma that has come back or not responded after 1 to 3 prior treatments. About 700 adults will take part to see which drug works better at shrinking tumors and delaying the cancer's return. Both treatments aim to control the disease, not cure it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Carmel Medical Center

    RECRUITING

    Haifa, 3436212, Israel

  • China Medical University Hospital

    RECRUITING

    Taichung, 40447, Taiwan

  • Highlands Oncology Group

    RECRUITING

    Springdale, Arkansas, 72762, United States

  • Medipol Mega University Hospital

    RECRUITING

    Istanbul, 34214, Turkey (Türkiye)

  • Nebraska Cancer Specialists

    RECRUITING

    Omaha, Nebraska, 68130, United States

  • Rambam Med.Center - Hematology Institute

    RECRUITING

    Haifa, 3109601, Israel

  • Taichung Veterans General Hospital

    RECRUITING

    Taichung, 40705, Taiwan

  • Taipei Veterans General Hospital

    RECRUITING

    Taipei, 112, Taiwan

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.